CG
GILD icon

Caprock Group’s Gilead Sciences GILD Stock Holding History

Caprock Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7M Sell
76,903
-28
-0% -$3.92K 0.26% 64
2025
Q4 		$9.44M Buy
76,931
+12,895
+20% +$1.57M 0.2% 79
2025
Q3 		$7.23M Buy
+64,036
New +$7.28M 0.18% 94
2025
Q1 		$5.54M Buy
49,445
+7,076
+17% +$730K 0.17% 104
2024
Q4 		$3.91M Buy
42,369
+3,970
+10% +$357K 0.13% 135
2024
Q3 		$3.22M Sell
38,399
-1,778
-4% -$136K 0.12% 151
2024
Q2 		$2.76M Buy
40,177
+12,286
+44% +$820K 0.11% 154
2024
Q1 		$2.04M Buy
27,891
+687
+3% +$52.8K 0.12% 129
2023
Q4 		$2.2M Buy
27,204
+40
+0.1% +$3.11K 0.14% 118
2023
Q3 		$2.04M Sell
27,164
-1,782
-6% -$137K 0.15% 95
2023
Q2 		$2.23M Buy
28,946
+623
+2% +$49.7K 0.16% 95
2023
Q1 		$2.35M Buy
28,323
+1,855
+7% +$154K 0.18% 84
2022
Q4 		$2.27M Buy
26,468
+67
+0.3% +$5.31K 0.21% 76
2022
Q3 		$1.63M Buy
26,401
+2,943
+13% +$186K 0.16% 93
2022
Q2 		$1.45M Buy
23,458
+3,087
+15% +$191K 0.14% 109
2022
Q1 		$1.21M Buy
20,371
+753
+4% +$48.1K 0.11% 142
2021
Q4 		$1.43M Sell
19,618
-1,174
-6% -$80.9K 0.12% 126
2021
Q3 		$1.45M Sell
20,792
-1,890
-8% -$133K 0.13% 111
2021
Q2 		$1.56M Buy
22,682
+10,329
+84% +$690K 0.14% 111
2021
Q1 		$798K Buy
12,353
+4,060
+49% +$262K 0.09% 170
2020
Q4 		$483K Sell
8,293
-5,666
-41% -$342K 0.06% 234
2020
Q3 		$882K Sell
13,959
-12,871
-48% -$893K 0.12% 136
2020
Q2 		$2.06M Buy
26,830
+4,061
+18% +$311K 0.31% 63
2020
Q1 		$1.7M Buy
22,769
+15,103
+197% +$1.04M 0.32% 60
2019
Q4 		$498K Sell
7,666
-957
-11% -$62.3K 0.09% 162
2019
Q3 		$547K Buy
8,623
+714
+9% +$46.7K 0.11% 146
2019
Q2 		$534K Buy
7,909
+2,452
+45% +$161K 0.1% 153
2019
Q1 		$355K Buy
5,457
+678
+14% +$45.1K 0.07% 234
2018
Q4 		$299K Buy
4,779
+247
+5% +$17.3K 0.07% 244
2018
Q3 		$350K Sell
4,532
-435
-9% -$32.9K 0.07% 237
2018
Q2 		$352K Buy
4,967
+899
+22% +$63.5K 0.07% 249
2018
Q1 		$307K Buy
4,068
+12
+0.3% +$954 0.07% 270
2017
Q4 		$321K Sell
4,056
-982
-19% -$74.6K 0.06% 279
2017
Q3 		$408K Buy
5,038
+499
+11% +$38.2K 0.09% 221
2017
Q2 		$321K Sell
4,539
-6,999
-61% -$466K 0.07% 261
2017
Q1 		$784K Sell
11,538
-228
-2% -$16K 0.18% 105
2016
Q4 		$843K Sell
11,766
-819
-7% -$60.9K 0.21% 97
2016
Q3 		$996K Buy
12,585
+6,409
+104% +$521K 0.23% 104
2016
Q2 		$515K Sell
6,176
-1,441
-19% -$128K 0.13% 156
2016
Q1 		$700K Buy
+7,617
New +$687K 0.17% 127
2015
Q3 		– Sell
-4,967
Closed -$582K – 85
2015
Q2 		$582K Buy
4,967
+1,208
+32% +$132K 0.53% 37
2015
Q1 		$369K Hold
3,759
– – 0.38% 51
2014
Q4 		$354K Buy
+3,759
New +$389K 0.38% 55

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Caprock Group's GILD Position: Q1 2026 in Review

Caprock Group reduced its Gilead Sciences (GILD) stake by 0.04% in Q1 2026, selling an estimated $3.92K and leaving 76,903 shares worth $10.7M. The position accounts for 0.26% of the portfolio, ranked #64.

Caprock Group first reported a position in GILD in Q4 2014 and has held it in 43 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Caprock Group held 76,903 shares of Gilead Sciences worth $10.7M as of Q1 2026.
  • Caprock Group sold 28 Gilead Sciences shares in Q1 2026, an estimated $3.92K.
  • Gilead Sciences made up 0.26% of Caprock Group's portfolio in Q1 2026, its #64 holding.
  • Caprock Group first reported a position in Gilead Sciences in Q4 2014 and has held it in 43 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.